C. Richard Lyttle
9Patents
6h-index
16Co-inventors
60Inventor score
Filing activity: Jun 2, 1995 → Dec 24, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7803770B2 | Method of treating osteoporosis comprising administration of PTHrP analog | Human Necessities | 26 | Active |
| US7531564B2 | Substituted benzoxazoles as estrogenic agents | Chemistry; Metallurgy | 25 | Active |
| US8148333B2 | Stable composition comprising a PTHrP analogue | Human Necessities | 20 | Active |
| US8748382B2 | Method of drug delivery for bone anabolic protein | Human Necessities | 17 | Active |
| US8933130B2 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | Human Necessities | 16 | Active |
| US5877284A | Isolated chemotactic factor from patients with endometriosis | Emerging Cross-Sectional Technologies | 7 | Expired |
| US9555014B2 | Therapeutic regimens | Human Necessities | 3 | Active |
| USRE49444E1 | Method of treating osteoporosis comprising administration of PTHrP analog | General | 2 | Active |
| US5891644A | Antibody specific for an isolated chemotactic factor from patients with endometriosis | Emerging Cross-Sectional Technologies | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.